Income Statement
Unit : KRW million
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Revenue | 157,544 | 236,120 | 168,310 |
| Operating income | 4,077 | 44,282 | 36,343 |
| Net income before taxes | -7,464 | 36,508 | 39,533 |
| Net income | 79 | 24,169 | 30,064 |
| Total comprehensive income | -317 | 26,477 | 32,215 |
GC Famliy Site
- Pharmaceutical GC Biopharma GC Cell
- Healthcare GC Wellbeing GC Care UB care Able Analytics
- Diagnosis GCMS GC Medis GC Genome GCCL GreenVet Genes Laboratories
- Overseas GC China GC China Pharm GC LabTech GC Biopharma USA Curevo GC Lymphotech GC Biopharma do Brasil Ativa Biotherapeutics, Inc. BioCentriq
- Foundation MOGAM Institute for Biomedical Research Mogam Science Scholarship Foundation GC I-MED
- Moreover GCEM GC Invacfarm
Email Opt-Out
If any of the email addresses posted on this website are used to collect unauthorized email addresses through the use of email harvesting programs or other technical devices, the Company through the use of electronic collection programs or other technical devices, and please note that violations of the Information and Communications Network Act are criminally punishable.
Financial Information
Balance Sheet
Unit : KRW million
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Current assets | 63,888 | 93,327 | 96,842 |
| Long-term assets | 601,286 | 583,204 | 548,733 |
| Total assets | 665,173 | 676,531 | 645,575 |
| Current liabilities | 76,816 | 88,116 | 84,042 |
| Long-term liabilities | 46,876 | 42,668 | 45,849 |
| Total liabilities | 123,692 | 130,784 | 129,891 |
| Total capital | 541,482 | 545,747 | 515,684 |